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Background – Moisturizers are foundational therapies for human atopic dermatitis. In veterinary medicine, the
use of moisturizers has been recommended by an expert committee to alleviate skin dryness that would occur,
for example, in canine atopic dermatitis (cAD). However, little is known regarding the effects of moisturizers on
the skin barrier.
Hypothesis/Objectives – To investigate the effects of a moisturizer on skin barrier recovery in a canine model
of chronic mechanical barrier disruption.
Animals – Six healthy beagle dogs maintained in a laboratory setting.
Methods and materials – A model of chronic skin barrier disruption was simulated by tape stripping on both
sides of the thorax. The moisturizer then was applied twice daily for one week to one side of the thorax, while
the other hemithorax was left untreated. The effects were evaluated by measurement of transepidermal water
loss (TEWL) at various times during skin barrier recovery, and by histological assessment of the disrupted skin
one week after moisturizer application.
Results – Overall, TEWL was reduced, epidermal thickness was lower, stratum corneum thickness was greater
and the intensity of the dermal inflammatory infiltrate was reduced for treated sites.
Conclusions and clinical importance – These results suggest a potential benefit of the moisturizer for improv-
ing skin barrier function, which is frequently altered in chronic inflammatory dermatoses such as cAD.
Introduction
An intact skin barrier is critical to prevent desiccation from
excessive water loss and the penetration of exogenous
substances detrimental to the body. This barrier is con-
trolled mainly by the outermost layer of the epidermis,
the stratum corneum (SC), composed of corneocytes sur-
rounded by complex lipid lamellae.1,2
The skin barrier has been shown to play a major role in
the pathogenesis of some inflammatory dermatosis,
especially canine atopic dermatitis (cAD). Several studies
of cAD have shown abnormalities in SC proteins (such as
filaggrin and its hygroscopic derivatives3,4) and in SC
lipids5 (including reduction in ceramides6 or disorganized
lamellar lipids7,8).
Moisturizers are a foundational therapy for human ato-
pic dermatitis (AD) and for maintenance of remission
from flares. When combined with topical corticosteroids,
moisturizers have been shown to be more effective than
topical corticosteroids alone.9 The terms “moisturizer”
and “emollient” often are used interchangeably to imply
the addition of water to the skin. Moisturizers may
increase SC hydration by two different mechanisms:
reduction of water loss through occlusion of the skin sur-
face by hydrophobic substances (e.g. mineral oils, petro-
latum ceramide, paraffin and silicone), or hydration of the
SC by humectants (e.g. propylene glycol, urea, glycerol or
glycerin, panthenol) which increase the water-binding
capacity of the SC.10
In veterinary medicine, the use of moisturizers for alle-
viation of skin dryness in cAD has been recommended,
especially after bathing.11,12 However, little is known
regarding the effects of moisturizers on the canine skin
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barrier; most published studies have evaluated the occlu-
sive effects of lipid-containing topical formulations and
not humectants.13–19 Efficacy of moisturizers can be
assessed either in clinical studies or in experimental mod-
els with artificially damaged skin. In humans,20 laboratory
animals21 and dogs,22 mechanical disruption of the skin
barrier can be generated by removing the SC through
repeated applications of adhesive tape, a procedure
known as tape stripping (TS). The integrity and the
restoration of the skin barrier function then can be
assessed in different ways. One of the most common
noninvasive methods used in human studies is the mea-
surement of transepidermal water loss (TEWL),23 which
is well correlated with skin barrier impairment.24 In dogs,
TEWL also has been used widely for the evaluation of
skin barrier integrity.5,22,25,26
Ermidra spray (ICF; Palazzo Pignano, Italy) is one of
many moisturizers available for veterinary use and is indi-
cated for xerosis in dogs. The primary components of this
product are humectants including glycerol, dexpanthenol
and propylene glycol, which are either freely distributed in
the product or micro-encapsulated by cyclodextrins and
liposomes (which are intended to enhance penetration
and provide progressive release of the moisturizing
agent). The aim of this study was to investigate the
in vivo effect of the moisturizer on the recovery of the
skin barrier function and inflammation induced by TS,
through evaluation of TEWL measurement and
histopathological examination of skin biopsies.
Methods and materials
All procedures were approved by the Institutional Animal Care and
Use Committee of our institute. (Ethics committee reference number
1021).
Animals
Six healthy, male, 2-year-old beagle dogs weighing 7 to 12 kg were
used for these studies. None of the dogs had a history or current evi-
dence of skin lesions, and had not received any systemic or topical
therapies within the three months preceding the study. The dogs
belonged to a research colony housed indoors in a temperature- and
humidity-controlled facility (25–28°C, relative humidity 40–60%) and
were housed in individual cement runs which were cleaned twice
daily. Twelve weeks before and throughout the course of the study
the dogs were fed the same maintenance dry food regimen (Specific
Adult medium breed, Dechra Veterinary Products; Montigny le Bre-
tonneux, France) and tap water ad libitum. One week before the
beginning of the study, the dogs were acclimatized to their environ-
ment.
Tape stripping
The TS of the SC for barrier disruption was performed using a com-
mercial adhesive tape (19 mm Scotch Transparent Tape, 3M; Cergy,
France). At each test site, a new piece of tape was applied, pressed
on with finger pressure for 10 s, then removed in one swift
motion.22
Experimental procedure
The lateral thorax was selected as the test site because it provided
adequate surface area for TS, skin biopsy and a horizontal orientation
for the evaporimeter probe. In addition, TS in this area triggered little
response from the dog and was less likely to be licked. The hair was
gently clipped using an electric hair clipper (Favorita II GT 104, Aescu-
lap; Sulh, Germany) 24 h before the start of the study in order to
minimize any effect of recent hair clipping. The same investigator
performed all procedures and measurements in order to minimize
variability. Six sites were evaluated on each hemithorax (12 sites in
total). Sites were approximately 4 cm2 and spaced 3 cm apart. Each
site was stripped until TEWL reached 50 g/m2/h. This procedure was
carried out once a day for seven consecutive days.
From Day 7 to Day 13, 1 mL of moisturizer was applied on the six
sites located on the right hemithorax every 12 h. On the left hemitho-
rax, sites were left untreated as a control.
TEWLmeasurements
The TEWL was measured four times at each of the 12 sites on
Day 7: just before the first application of the moisturizer (T0) and
2, 4 and 8 h after application (T2, T4 and T8). TEWL then was
measured once daily until Day 15 (T24 to T192). Measurements
were made using a portable, battery operated, closed, unventilated
chamber evaporimeter (VapoMeter SWL4001TJ, Delfin Technolo-
gies Ltd; Kuopio, Finland). The evaporimeter was activated by
pressing a single button, after which its probe placed directly onto
the skin, perpendicular to the surface. The 1 cm diameter of probe
was positioned in the centre of the 2 cm diameter (4 cm2) test
area for the measurement. The pressure applied to the probe was
sufficient to prevent air leakage between the probe and the skin.
The device automatically determined the measurement duration
and signalled completion with an audible tone.22 Measurements
were repeated consecutively three times and the mean of the
three measurements was used as a representative value.14,16,18,22
When there was a variation >15% between the three measure-
ments, they were repeated.
All measurements were performed in an air-conditioned room
where the temperature and humidity were identical to those in the
dog’s living area. Before each measurement, the dogs were acclima-
tized to experimental conditions for 15–20 min and they were not
allowed to exercise during the hour before the measurements.
Histological examination
For five of the six dogs, one skin biopsy was collected from each
hemithorax after the final TS and repeated on days 7 and 15 (end of
study). Skin biopsy specimens were collected using a 6 mm skin
punch under local anaesthesia induced by subcutaneous injection of
lidocaine (Xylovet, Ceva; La Ballastiere, France). Specimens were
fixed in 10% neutral buffered formalin for 24 h, embedded in paraf-
fin, routinely processed in the laboratory, sectioned at 4 lm thick-
ness and stained with Haematoxylin & Eosin. All skin biopsy
specimens were examined in a blinded fashion by two of the authors.
One section of tissue was examined per slide. The following
histopathological changes weresevaluated and scored: thickness and
nature of the SC, thickness of the epidermis and intensity of the der-
mal inflammatory infiltrate (Table 1). Epidermal and SC thicknesses
were determined using IMAGEJ software https://imagej.nih.gov/ij/.
Three measurements were performed randomly through the epider-
mis present on the section and the mean of the three values was
taken as representative.
Statistical analysis
All analyses were performed using R Development Core Team
(2008) R: A language and environment for statistical computing (R
Foundation for Statistical Computing; Vienna, Austria). To test the
effect of the moisturizer on the three quantitative variables TEWL,
epidermal thickness and SC thickness, we used three generalized
mixed models (linear, GLMM; additive, GAMM) using the lmer() func-
tion of the R/LME4 package and the gamm() function of the R/MGCV
package, respectively. We chose GLMM and GAMM for two main
reasons. First, mixed models were implemented because two group-
ing variables (“Dog” and “Site” on each dog) needed to be specified
with a random effect to take into account the nonindependence
between measures made at the same site and on the same dog.
Second, we selected a GAMM over a GLMM for the first model
because one explanatory variable (“Time”) was expected to have a
nonlinear effect on the response variable (log-transformation of the
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TEWL). Furthermore, GLMM and GAMM also allowed use of a con-
tinuous autoregressive correlation structure for the “Time” covari-
ate.
In the TEWL GAMM, the log-transformation of the TEWL was
used as the response variable with a normal distribution because it
was normally distributed for nine of 12 groups of measures (T0 to
T192, Shapiro–Wilk normality test), whereas the TEWL was normally
distributed for only three of 12 groups of measurements. The treat-
ment (moisturizer or control) was used as an explanatory variable
with a fixed effect in order to test the impact of the moisturizer on
the TEWL. “Time” was used as an explanatory variable with a nonlin-
ear fixed effect because TEWL was expected to decrease faster in
the first days than in the later days when the skin barrier was closer
to full recovery. “Site” and “Dog” were used as random effects to
take into account nonindependence between measures made at the
same site and on the same dog. We used a continuous autoregres-
sive correlation structure for the “Time” covariate in order to take
into account the correlation between the successive measures of
TEWL made at the same site of the same dog.
Epidermal thickness was used as the response variable with a nor-
mal distribution in the GLMM model (Shapiro–Wilk normality test,
P = 0.4553). The treatment (moisturizer or control) was used as an
explanatory variable with a fixed effect in order to test the impact of
the moisturizer on epidermal thickness. “Dog” was used as a ran-
dom effect to take into account the nonindependence between mea-
sures made on the same dog.
The SC thickness was used as response variable in the GLMM
model, with a normal distribution (Shapiro–Wilk normality test,
P = 0.6911). The treatment (moisturizer or control) was used as an
explanatory variable with a fixed effect in order to test the impact of
Ermidra on the SC thickness. “Dog” was used as a random effect to
take into account the nonindependence between measures made on
the same dog. All equations are provided in the Supporting Informa-
tion.
Finally, to test the impact of the moisturizer on the categorical vari-
able “Intensity” of the dermal inflammatory infiltrate (including cate-
gories 0 to 3) we used a Kruskal–Wallis rank sum test.
Results
TEWLmeasurement
Before disruption of the skin barrier, the mean TEWL of
the six dogs was 11 g/m2/h. Overall, TEWL was lower
for moisturizer-treated sites than control sites (Figure 1a).
Results from the TEWL GAMM showed this difference
was significant for the quantitative variable tested
(TEWL; Table 2). Moreover, a faster decrease in TEWL
was observed during the first 24 h for moisturizer-trea-
ted sites (Figure 2a, b). Interestingly, a short rise of the
TEWL was noticed, based on visual inspection, at T8 on
the control sites, yet this rise was not observed on mois-
turizer treated sites. On Day 15, TEWL values had
returned to normal on both moisturizer treated and con-
trol sites. For the TEWL GAMM, “Time” also had a sig-
nificant effect, where TEWL decreased with time
(Figure S1).
Histopathological results
The application of the moisturizer decreased the intensity
of epidermal hyperplasia. Overall, the epidermal thickness
was thinner for moisturizer-treated sites (Figure 1c).
Results from the epidermal thickness GLMM showed
this difference was significant for the quantitative variable
tested (Table 2). In the control sites, the epidermis
retained a more proliferative appearance with the pres-
ence of small rete ridges (Figure 3b).
The application of the moisturizer also increased the
restoration of the SC. Overall, SC thickness was greater
for moisturizer-treated sites (Figure 1b). Results from the
SC thickness GLMM showed that these differences were
significant for the quantitative variable tested (Table 2). In
the moisturizer-treated sites, the SC had more layers and
had a basket weave appearance closer to normal (Fig-
ure 3a). However, in the control sites, the SC was thinner
and more compact (Figure 3b). Finally, the application of
the moisturizer was associated with a significant
decrease in the intensity of the dermal inflammation
(Kruskal–Wallis v2 = 10.5281, d.f. 1, P= 0.001176) (Fig-
ure 1d). The inflammatory infiltrate induced by chronic
barrier disruption was almost absent in Ermidra-treated
sites, whereas it persisted, with moderate intensity, in
control sites (Figure 3a, b).
Discussion
This canine model of chronic mechanical skin barrier dis-
ruption allowed us to investigate the effect of the mois-
turizer Ermidra on both the restoration of the skin barrier,
assessed by TEWL measurements, and the inflammatory
modifications induced by chronic disruption, assessed by
histopathological examination.
The study showed that the moisturizer tested could be
indicated for promoting skin barrier restoration and for
alleviating cutaneous inflammation. All parameters evalu-
ated, including TEWL, epidermal thickness, SC thickness
and dermal inflammatory intensity scores, improved in
treated sites compared to control sites. Interestingly, a
short duration peak in TEWL was noticed, based on visual
inspection at 8 h on the control sites; this may have rep-
resented a measurement error.
In murine models, three phases of barrier recovery with
distinct metabolic activities occur after acute barrier dis-
ruption. The first phase is initiated by secretion of a pre-
formed pool of lamellar bodies which leads to a rapid
decrease of TEWL values.29 In the second phase,
increased lipid synthesis and accelerated lamellar body
formation and secretion lead to a slower decrease of
TEWL values.30 During the final phase, increased
Table 1. Histopathological changes evaluated before and after stratum corneum (SC) barrier disruption.
Grade Definition
SC thickness Epidermal thickness (µm): mean of three measurements for one section
Nature of the SC Basket weave or compact
Epidermal thickness Epidermal thickness (µm): mean of three measurements for one section
Intensity of the dermal inflammatory infiltrate 0: No infiltrate
1: Mild infiltrate
2: Moderate infiltrate
3: Severe infiltrate
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keratinocyte proliferation31 and differentiation complete
the skin barrier recovery and the TEWL value returns to
baseline levels.32 However, in chronic barrier disruption
the second phase could be stronger than in the acute situ-
ation, leading to a small increase in TEWL values rather
than a slower decrease. The use of moisturizers might
avoid this TEWL increase during the restoration of the
skin barrier.
Few clinical and experimental studies have been con-
ducted using moisturizers on dogs and even fewer have
used TEWL measurements to evaluate the skin barrier
integrity. Results have been inconsistent. Randomized,
double-blinded, placebo-controlled studies have evalu-
ated the effects of topical blackcurrant emulsion (en-
riched in essential fatty acids, ceramides and 18-beta
glycyrrhetinic acid),16 a topical lipid complex therapy,13
and topical demethicone14 on barrier function of dogs
with cAD. All failed to demonstrate significant improve-
ment in skin barrier function as measured by TEWL. By
contrast, TEWL values were significantly decreased in
Figure 1. (a–c) Boxplots of treated and control sites: (a) for transepidermal water loss (TEWL), (b) for stratum corneum thickness and (c) for epi-
dermis thickness.
For each boxplot the median (line within the box), first and third quartiles (box), nonoutlier range (whiskers) and outliers (dot) are shown.
(d) Classification of inflammatory cells at treated and control sites as assessed by histopathological investigation.
The intensity of the dermal inflammatory infiltrate was categorized as: 0 no infiltrate; 1 mild infitrate; 2 moderate infiltrate; and 3 severe infiltrate.
Table 2. Results from the three generalized mixed models to evaluate the effects of stratum corneum barrier disruption and application of a mois-
turizing agent.
Model type Response variable Explanatory variable Model coefficient 95% confidence interval P-value
GAMM1 log(TEWL) Treatment =moisturizer –0.081 [–0.0978; –0.0643] < 2x10-16
Time (s) n.a. n.a. < 2x10-16*
GLMM2 Epidermal thickness Treatment =moisturizer –8.767 [–10.53; 7.008] 7.31x10-14
GLMM3 SC thickness Treatment =moisturizer 7.95 [5.176; 10.72] 5.77x10-7
n.a., not assessed; TEWL, transepidermal water loss.
1
Generalized additive mixed model (GAMM): logTEWL ~ s(Time) + Treatment.
2
Generalized linear mixed model (GLMM): Epidermal thickness ~ Treatment.
3
Generalized linear mixed model: SC thickness ~ Treatment.
*Approximate significance of smooth terms given by the gamm() function.
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two open clinical studies evaluating a ceramide-based
moisturizer in dogs with cAD,15 and a spray containing
unsaturated fatty acids and essential oils.19 One study
demonstrated a positive impact on skin inflammation
after application of an emulsion in a canine model of
chronic barrier disruption, and failed to show any impact
on TEWL measurements.18
Humectants, by absorbing water, can stimulate a
water flux which creates a stimulus for barrier
repair.10 One of the main hygroscopic components of
the moisturizer is glycerol. Glycerol interacts with the
SC lipid structures or with proteins, altering their own
water-bonding and hydrophilic properties.27 It also pro-
motes lamellar body secretion, modifies the plasticity
of SC lipids, and has keratolytic effects.27 The moistur-
izer also contains propylene glycol which is known to
have a partial occlusive effect.33 This combination
allows for the creation of an artificial film on the skin
surface until the defective barrier is repaired in order
to maintain adequate stratum corneum hydration.
Moreover, it is possible that some components of the
moisturizer also could directly stimulate lipid metabo-
lism. Dexpanthenol, for example, is a precursor of vita-
min B5, a component of coenzyme A that catalyzes
early steps in the synthesis of fatty acids and sphin-
golipids which are of critical importance for SC lipid
bilayers.28 Lastly, based on the results of the present
study, the moisturizer could act on the changes
induced by the chronic skin barrier disruption, namely
the epidermal hyperplasia and dermal inflammation,
which also promote SC restoration. Numerous epider-
mal cytokines probably are involved in the inflamma-
tory changes observed in chronic barrier disruption.
Some components of the moisturizer, such as dexpan-
thenol28 and zinc gluconate34, have anti-inflammatory
properties that could contribute to the decrease of
dermal inflammation.
In conclusion, the application of the moisturizer Ermidra
both improved the restoration of the skin permeability
barrier and decreased the inflammatory changes noted in
a model of chronic SC barrier disruption. Because similar
lesions and functional changes are observed in inflamma-
tory dermatoses, the results of this study are useful in
understanding the effects of moisturizers on the skin bar-
rier and their significant role in the management of inflam-
matory dermatoses, particularly cAD.
Figure 2. Transepidermal water loss (TEWL) values for skin treated
with control and moisturizer agent.
(a) Effect of treatment on the recovery of the skin permeability barrier
over time. The data represent the mean values  95% confidence
interval from the six dogs. (b) Close-up on the first 24 h.
a b
Figure 3. Histopathological changes in the skin of Dog 3 after treatment with control or moisturizer.
(a) After seven days of moisturizer application, the epidermis thickness was near normal, and the stratum corneum (SC) had more layers and had a
basket weave appearance closer to normal. Haematoxylin & Eosin. Scale bar, 100 µm. (b) After seven days of treatment for the contralateral side,
the epidermis in the control (untreated) site was moderately acanthotic with small rete ridges, and the SC was thinner and more compact than in
moisturizer-treated sites. H&E. Scale bar, 100 µm.
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Resume
Contexte – Les hydratants sont des traitements fondamentaux de la dermatite atopique humaine. En
medecine veterinaire, l’utilisation d’hydratants a ete recommandee par un comite d’expert pour soulager la
secheresse cutanee qui pourrait se developper, par exemple, dans la dermatite atopique canine (CAD).
Cependant, les effets des hydratants sur la barriere cutanee sont peu connus.
Hypotheses/objectifs – Determiner les effets d’un hydratant sur la restauration de la barriere cutanee
dans un modele canin de dysfonction de barriere mecanique chronique.
Sujets – Six chiens beagles sains de laboratoire.
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Materiels et methodes – Un modele de dysfonction de barriere cutanee a ete simule par test a la cello-
phane adhesive sur les deux faces du thorax. L’hydratant a ensuite ete applique deux fois par jour pendant
une semaine a un cote du thorax, tandis que l’autre cote n’etait pas traite. Les effets ont ete evalues par la
mesure de la perte d’eau trans-epidermique (TEWL) a des temps differents au cours de la reparation de la
barriere cutanee et par examen histopathologique de la peau lesee une semaine apres application de
l’hydratant.
Resultats – La TEWL a ete reduite, l’epaisseur epidermique etait plus faible, l’epaisseur de la couche
cornee etait plus importante et l’intensite de l’infiltrat inflammatoire dermique etait reduite pour les sites
traites.
Conclusions et importance clinique – Ces resultats suggerent un benefice potentiel de l’hydratant pour
ameliorer la fonction barriere cutanee, frequemment alteree dans les dermatoses inflammatoires chroni-
ques telles que la CAD.
RESUMEN
Introduccion – las cremas hidratantes son terapias fundamentales para la dermatitis atopica humana. En
medicina veterinaria, el uso de humectantes ha sido recomendado por un comite de expertos para aliviar la
sequedad de la piel que ocurrirıa, por ejemplo, en la dermatitis atopica canina (cAD). Sin embargo, se sabe
poco sobre los efectos de las cremas hidratantes en la barrera cutanea.
Hipotesis/Objetivos – investigar los efectos de un humectante sobre la recuperacion de la barrera
cutanea en un modelo canino de alteracion cronica de la barrera mecanica.
Animales – Seis perros beagle sanos mantenidos en un laboratorio.
Metodos y materiales – se simulo un modelo de alteracion cronica de la barrera cutanea mediante cinta
adhesiva en ambos lados del torax. La crema hidratante se aplico dos veces al dıa durante una semana a un
lado del torax, mientras que el otro hemitorax no se trato. Los efectos se evaluaron mediante la medicion
de la perdida de agua transepidermica (TEWL) en varios momentos durante la recuperacion de la barrera
cutanea, y mediante la evaluacion histologica de la piel alterada una semana despues de la aplicacion de la
crema hidratante.
Resultados – en general, la TEWL se redujo, el grosor epidermico fue menor, el grosor del estrato corneo
fue mayor y la intensidad del infiltrado inflamatorio dermico se redujo para los sitios tratados.
Conclusiones e importancia clınica – estos resultados sugieren un beneficio potencial de la crema hidra-
tante para mejorar la funcion de barrera cutanea, que con frecuencia se altera en dermatosis inflamatorias
cronicas como la cAD.
Zusammenfassung
Hintergrund – Feuchtigkeitscremes stellen in der Humanmedizin f€ur die atopische Dermatitis eine funda-
mentale Therapie dar. In der Veterin€armedizin wurde die Verwendung von Feuchtigkeitscremes von einem
ExperteInnen Komitte empfohlen, um die Trockenheit der Haut zu mildern, zum Beispiel bei der caninen
atopischen Dermatitis (cAD). Es ist jedoch wenig bekannt €uber die Auswirkungen der Feuchtigkeitscremes
auf die Hautbarriere.
Hypothese/Ziele – Eine Untersuchung der Wirksamkeit von Feuchtigkeitsspendern auf die Wiederherstel-
lung der Hautbarriere nach chronischer mechanischer Zerst€orung der Hautbarriere in einem Hundemodell.
Tiere – Seches gesunde Beagles, die in einem Untersuchungslabor gehalten wurden.
Methoden und Materialien – Das Modell einer chronischen Zerst€orung der Hautbarriere wurde mittels
Klebestreifenabtragung an beiden Seiten des Thorax simuliert. Der Feuchtigkeitsspender wurde danach
zweimal t€aglich eine Woche lang auf einer Seite des Thorax aufgetragen, w€ahrend die andere Thoraxseite
unbehandelt blieb. Die Auswirkungen wurden mittels Messung des transepidermalen Wasserverlustes
(TEWL) zu unterschiedlichen Zeiten w€ahrend der Erholung der Hautbarriere evaluiert und mittels histologi-
scher Beurteilung der zerst€orten Haut eine Woche nach Anwendung des Feuchtigkeitsspenders beurteilt.
Ergebnisse – Insgesamt war die TEWL reduziert, die epidermale Dicke niedriger, die Dicke des Stratum
corneum erh€oht und die Intensit€at des dermalen Entz€undungsinfiltrates an mit behandelten Stellen redu-
ziert.
Schlussfolgerungen und klinische Bedeutung – Diese Ergebnisse weisen auf eine m€ogliche positive
Auswirkung des Feuchtigkeitsspenders zur Verbesserung der Funktion der Hautbarriere hin, die bei chroni-
schen entz€undlichen Dermatosen wie bei der cAD h€aufig ver€andert ist.
摘要
背景 – 湿剂是人类异位性皮炎的基础治疗。在兽医领域, 专家委员会建议使用保湿剂缓解犬异位性皮炎
(cAD)可能发生的皮肤干燥。然而, 关于保湿剂对皮肤屏障的影响知之甚少。
假设/目的 – 研究在慢性机械屏障破坏犬模型中, 保湿剂对皮肤屏障恢复的影响。
动物 – 在实验室环境中饲养的6只健康比格犬。
方法和材料 – 通过胸部两侧胶带剥离, 模拟慢性皮肤屏障破坏模型。然后在一侧胸部涂抹保湿剂, 每日两次,
持续一周, 而另一侧胸部不作处理。在皮肤屏障恢复期的不同时间测量经表皮水分流失 (TEWL), 并在应用保
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湿剂后一周对破坏皮肤进行组织学评估, 对保湿剂影响进行评价。
结果 – 总体而言, 治疗部位的TEWL减少, 表皮厚度降低, 角质层厚度增加, 真皮层炎性浸润强度降低。
结论和临床重要性 – 这些结果表明保湿剂对改善皮肤屏障功能具有潜在益处, 而皮肤屏障功能在慢性炎症性
皮肤病（如cAD）中经常发生改变。
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Resumo
Contexto – Os hidratantes s~ao terapias fundamentais para a dermatite atopica em humanos. Na medicina
veterinaria, o uso de hidratantes foi recomendado por um comite^ de especialistas para aliviar o resseca-
mento da pele que pode ocorrer, por exemplo, na dermatite atopica canina (DAC). No entanto, pouco se
sabe sobre os efeitos dos hidratantes na barreira da pele.
Hipotese / Objetivos – Investigar os efeitos de um hidratante na recuperac~ao da barreira cuta^nea em um
modelo canino de ruptura meca^nica cro^nica da barreira.
Animais – Seis c~aes beagle saudaveis mantidos em laboratorio.
Metodos e materiais – Um modelo de ruptura cro^nica da barreira cuta^nea foi simulado utilizando fita ade-
siva em ambos os lados do torax. O hidratante foi aplicado duas vezes ao dia por uma semana em um lado
do torax, enquanto o outro hemitorax foi deixado sem tratamento. Os efeitos foram avaliados pela men-
surac~ao da perda de agua transepidermica (TEWL) em varios momentos durante a recuperac~ao da barreira
cuta^nea e pela avaliac~ao histologica da pele alterada uma semana apos a aplicac~ao do hidratante.
Resultados – De maneira geral, a TEWL foi reduzida, a espessura epidermica foi menor, a espessura do
estrato corneo foi maior e a intensidade do infiltrado inflamatorio dermico foi reduzida nos locais tratados.
Conclus~oes e importa^ncia clınica – Esses resultados sugerem um benefıcio potencial do hidratante para
melhorar a func~ao da barreira cuta^nea, que e frequentemente alterada nas dermatoses inflamatorias cro^ni-
cas, como a DAC.
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